Research has shown that there are few clinical comparisons available between the drugs for ADHD. As a result, parents seeking the best individual drug for their children with attention deficit hyperactivity disorder // have little hard evidence to help make that choice.
There are few head-to-head clinical comparisons of many ADHD medications, despite the relatively large variety of drugs prescribed for ADHD and the prevalence of the condition among children and adults, according to a new review from the Oregon Evidence-based Practice Center at the Oregon Health and Science University.
The Oregon Evidence-based Practice Center makes available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes.
The majority of the head-to-head trials identified by the Oregon reviewers compared the widely prescribed ADHD medication Ritalin with other drugs. Most of these comparative trials were short in duration, included only a small number of patients and did not measure the long-term effects of the drugs.
As for safety, the researchers found that short-term, randomized controlled trials do not provide clear evidence that any one stimulant is any more tolerable than another or that non-stimulants are more tolerable than stimulants.
None of the trials compared how well the drugs performed in terms of improving academic performance, quality of life or social skills, the researchers found.
Stimulant medications such as Ritalin and amphetamines are most often prescribed for ADHD, but the Oregon study includes several types of ADHD medications that have never been examined before in a systematic review, including newer stimulants such as modafinil and non-stimulant drugs such as Strattera (atomoxetine), antihypertensive drugs such as guanfacine and older antipsychotic drugs such as clozapine.
Limited evidence suggests that the antihypertensive dr
ugs clonidine and guanfacine reduce the severity of facial tics in children with ADHD, but the two drugs are not approved by the Food and Drug Administration for the treatment of ADHD.
Source: Newswise Related medicine news :1
. Clinical trials need to be more frank2
. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses 3
. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics4
. A Novel System For Clinical Banking Of Umbilical Cord Blood 5
. Clinical Renal Trails Do Not Have Sufficient Women Participants6
. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment7
. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand8
. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients9
. Cancer Clinical Research in India10
. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care11
. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed